Viventia Biotech Inc. is a privately held biopharmaceutical company specializing in the discovery and development of a new generation of advanced monoclonal antibody products designed to offer safer, more beneficial therapies for those who suffer from cancer. Our lead product candidate Proxinium™ is in multiple clinical studies, including a Phase III clinical trial for the treatment of head and neck cancer.  Vicinium™ is in a Phase II clinical study for the treatment of bladder cancer, and VB6-845 is in a Phase I/II clinical trial for the treatment of solid tumors. Viventia is employing its novel monoclonal antibody discovery and development platforms to discover, validate and advance a portfolio of new antibody products based on proprietary oncology drug targets.